What’s attractive about stocks with a market value around $1 billion? The author of today’s article explains that “At that size, a stock is small enough so that it hasn’t yet been “discovered” by a lot of Wall Street firms, but big enough to have some heft and staying power.” Each year he selects ten stocks hovering around the billion-dollar…
Thanksgiving means it’s a shortened trading week – and today’s article features two biotech stocks to consider shorting this shortened week based on technical analysis and quantitative ratings. For these two biotech stocks that “look bearish and may present interesting investing opportunities on the short side,” CLICK HERE.
The three biotech stocks highlighted in today’s article are ones to watch carefully in the coming weeks, advises the author, as important news drops are expected – and in the case of two of the stocks, those news drops are related to the companies’ COVID-19 vaccine candidates. For more on these three biotech stocks to watch throughout the remainder of…
If the biotech titan that’s the focus of today’s article is going to improve its growth prospects, it may have to go acquisition shopping in the next few months – and one of the three companies that the author highlights could be its target, as he notes that all three are acquisitions that “the biotech could easily afford and that…
The clinical-stage biotech highlighted in today’s article, dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, has been one of the hottest biotech stocks this year. And after a run-up that has generated triple-digit returns, there are a number of factors that could help propel it to even higher highs from here. For more on this…
In making the case for why the biotech featured in today’s article, which is focused on the development of novel antibody-drug conjugate therapeutics for the treatment of cancer, is an attractive investment, the analyst cited points to three primary factors: “the favorable outlook for [its lead candidate], the long-term potential of the biotech’s pipeline and the continuing validation, by partners,…
The biotech stock that’s the focus of today’s article recently dipped after reporting clinical trial results for its revolutionary cancer treatment “that were positive but perhaps not positive enough to outrun the competition.” So could it represent a good “buy the dip” opportunity? The author outlines the reasons to consider buying this stock, as well as some reasons to exercise…
Investors looking for profitable pandemic plays have a plethora of biotech firms to choose from. The one that’s the subject of today’s article, however, may not be one of them, despite the fact that some are betting on it as a COVID play. In fact, one market analyst has warned “Investors beware” in regards to this stock. For the stock…
How important a factor is the outcome of the presidential election for the direction of stocks? Not as important as a COVID-19 vaccine, according to Goldman Sachs. With this in mind, today’s article highlights two therapeutics companies focused on battling neurodegenerative diseases where analysts at Goldman see significant upside potential. For these two stocks – both of which have earned…
As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering…